Dasatinib 化学構造
分子量: 488.01

高品質保証

文献中の引用(62)

カスタマーフィードバック(10)

Quality Control & MSDS

製品説明

  • Compare Src Inhibitors
    Src製品生物活性の比較
  • 研究分野
  • Combination Therapy
    併用療法

製品の説明

生物活性

製品説明 Dasatinib は、野生型ablとSrcのためのSrc/abl阻害剤で、IC50 がそれぞれ 0.6 nM と 0.8 nMです。
ターゲット Abl Src c-Kit (WT)/c-Kit (D816V)
IC50

0.6 nM

0.8 nM [1]

79 nM/37 nM [2]
In vitro試験 Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. [1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. [3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
M07ep210 NHv3bIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjQWWR1PzJiaB?= NWWzd5JxTE2VTx?= MUDJR|UxRTBwMECwNFch|ryP MV:xO|k2PjB6MB?=
K562 MnvCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TNbFczKGh? NYHZeFN3TE2VTx?= M{\RPGlEPTB;MD6wNFEh|ryP NVzKb3hMOTd7NU[wPFA>
M07e NFfqcI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTuPGUyPzJiaB?= M37SUmROW09? MkDYTWM2OD1yLkCwNVIh|ryP Mo\YNVc6PTZyOEC=
ALL3 MX3DfZRwfG:6aXOgRZN{[Xl? MkX5NE4y|ryP NULLTmFqPzJiaB?= M{XGPWROW09? MkO3TWM2OD1yLkCwNFQh|ryP NH:4VoUyQTh6OUW0NC=>
CML NG\6Z4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLiWHA5OjBibXnu NVy3[oFGTE2VTx?= MUDJR|UxRTBwMECxJO69VQ>? NU\wT5ozOTl{MUmwNVY>
BA/F3 M{niWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjrbGY4OiCq M4jsZ2ROW09? NVy5TIlGUUN3ME22MlU5QSEQvF2= NXHZW|luOjNyOEi2OFQ>
BA/F3 NWnVdWJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLMXm95PzJiaB?= MmfvSG1UVw>? NFq5S5BKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlGvSlMh[2WubIOg[ZhxemW|c3nu[{BD[3JvQXLsJG0{PTGWIH31eIFvfCC5aYToJGlEPTBib3[gNE4xODB6M988US=> NFfBb28zOzB6OE[0OC=>
BA/F3 MoLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLjXoI4OiCq Mn3YSG1UVw>? NUDQe|JiUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEKlcj3BZowhf2m2aDDJR|UxKG:oIECuNFA1Pc7:TR?= NIjoS5QzOzB6OE[0OC=>
BA/F3 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\zO|IhcA>? NF;QbopFVVOR MkDUTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy|IHX4dJJme3OrbnegRoNzNUGkbDDUN|E2USCvdYThcpQhf2m2aDDJR|UxKG:oIEGuO|E1|ryP M{Tp[FI{ODh6NkS0
BA/F3 MmDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXoR3c4OiCq NYTFWodxTE2VTx?= NGXIT3RKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCINEi2V{BufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFAxQc7:TR?= MVOyN|MxOTdyMx?=
BA/F3 M2nT[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPYbVBbPzJiaB?= MVTEUXNQ NH7BVm1KdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCHMkW1T{BufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFA{Os7:TR?= MljVNlM{ODF5MEO=
BA/F3 Mn3FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUe3NkBp NFLxU5pFVVOR Mn\nTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTzJ3MFWgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwOVHPxE1? MV6yN|MxOTdyMx?=
BA/F3 NUHpUHdbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnmO|IhcA>? MlvwSG1UVw>? NVjab4JTUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiUUK1NmghdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxQM7:TR?= MmDGNlM{ODF5MEO=
BA/F3 M2Dwfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fxSVczKGh? M2HZXWROW09? NE[5eWNKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCHM{W5WkBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFAyO87:TR?= NYnLOGptOjN|MEG3NFM>
BA/F3 MmTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nFeFczKGh? MnyxSG1UVw>? MkDrTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKHerbHSgeJlx\SCEQ2KtRWJNKGG|c3Xzd4VlKGG|IHfyc5d1cCCLbnjpZol1cW:wIIfpeIghUUN3MDDv[kAxNjByMUpOwG0> MlT6NlM{ODF5MEO=
BA/F3 M3\aeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fY[lczKGh? M4TOUWROW09? Mn7mTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhYTJ3M1igcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNlPPxE1? NXPrfplbOjN|MEG3NFM>
BA/F3 NVHzZVhMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHuOpJPPzJiaB?= NWH2Z|VrTE2VTx?= Mk\pTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhXDNzNVmgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iB|LkdOwG0> NUD0R2M2OjN|MEG3NFM>
BA/F3 NYq1O2xYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHCWWJ5PzJiaB?= MkC0SG1UVw>? MYjJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCyMlXPxE1? MVqyN|MxOTdyMx?=
T cell MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHmO|IhcA>? M{HoNmROW09? NU\m[2U3UW6qaXLpeJMh[W62aTDDSFMuKGGwZDDhcpRqKEOGMkitbY5lfWOnZDDUJINmdGxicILvcIln\XKjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFPPxE1? M374VVE4OTV2NUGy
WiDr MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LnSVczKGh? MVzEUXNQ MWrJR|UxRTBwMEWyJO69VQ>? MYqxOVYyPTVzMh?=
PC3 MkXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXjTnNGPzJiaB?= NX[1bmhKTE2VTx?= MX7JR|UxRTBwMEC5OEDPxE1? MoLaNVU3OTV3MUK=
MDA-MB-231 NIS1UW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjTOoJmPzJiaB?= MkLrSG1UVw>? NXXofVRiUUN3ME2wMlAyOiEQvF2= MXexOVYyPTVzMh?=
Hs578T M4TZd2N6fG:2b4jpZ{BCe3OjeR?= NFS2epY4OiCq MVjEUXNQ NH\BUXBIUTVyPUCuNFMh|ryP M2POXVI1ODF3M{K3
HMEC NHjqWYZEgXSxdH;4bYMhSXO|YYm= M3G3[lczKGh? M1nSWWROW09? M3PSSWdKPTB;MT64JO69VQ>? MXeyOFAyPTN{Nx?=
DU145 NH3ie3ZEgXSxdH;4bYMhSXO|YYm= M1fsfFczKGh? NHnobFJFVVOR Mn7aS2k2OD1yLkG2JO69VQ>? NHHsfY0zPDBzNUOyOy=>
U251 MYDDfZRwfG:6aXOgRZN{[Xl? M4joW|czKGh? M4HWZmROW09? M2rvNmdKPTB;Mj64NUDPxE1? M3rBbVI1ODF3M{K3
NCI60 MXfDfZRwfG:6aXOgRZN{[Xl? MlX4O|IhcA>? NH3JeJFFVVOR MmfjS2k2OD13Lkeg{txO MX:yOFAyPTN{Nx?=
MALME-3M M1jIUmN6fG:2b4jpZ{BCe3OjeR?= M3O5dFczKGh? MmfHSG1UVw>? M3XSV2dKPTB;Nj62NUDPxE1? MmDXNlQxOTV|Mke=
KM12 MmXvR5l1d3SxeHnjJGF{e2G7 MlqyO|IhcA>? MYPEUXNQ M4fmZmdKPTB;Nz60OEDPxE1? NIXQPWUzPDBzNUOyOy=>
SW620 M1XwZWN6fG:2b4jpZ{BCe3OjeR?= MUm3NkBp M2G0Z2ROW09? MmO4S2k2OD16LkSzJO69VQ>? MVuyOFAyPTN{Nx?=
RXF 393NL MnSwR5l1d3SxeHnjJGF{e2G7 NUPEOox4PCCmYYnz Ml3ESG1UVw>? MoXHTWM2OD1yLkCyNVch|ryP M2P3WFI{OjV|MEe0
LXFA 983L NEXsS4pEgXSxdH;4bYMhSXO|YYm= NV7xVFlsPCCmYYnz NFzzR|RFVVOR NXjGcZpiUUN3ME2wMlA2PjVizszN MY[yN|I2OzB5NB?=
PRXF DU145 MnLwR5l1d3SxeHnjJGF{e2G7 NUnMWI1GPCCmYYnz Mn7JSG1UVw>? MWTJR|UxRTBwME[yN{DPxE1? M2L6SVI{OjV|MEe0
PAXF 1657L M2f0fGN6fG:2b4jpZ{BCe3OjeR?= MWG0JIRigXN? M4LyRWROW09? MnXHTWM2OD1yLkGyNUDPxE1? M1rZV|I{OjV|MEe0
CXF 1103L NUXy[4x[S3m2b4TvfIlkKEG|c3H5 M3XkUVQh\GG7cx?= NGf6dlBFVVOR NYHCVVBUUUN3ME20MlM3KM7:TR?= NGLWcoszOzJ3M{C3OC=>
GXF251L MoDMR5l1d3SxeHnjJGF{e2G7 NFP0UII1KGSjeYO= MoPOSG1UVw>? M4\yVGlEPTB;Mj6yOUDPxE1? NX\V[nJ{OjN{NUOwO|Q>
NCI-H23 MoPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHz1dYU4OiCq MWXEUXNQ MUXJR|UxRTJwMkeg{txO NF;ZfFkzOzV{MUCyNC=>
HCT116 Ml;jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTFOY5xPzJiaB?= M3:4UGROW09? NYe5eVBEUUN3ME2yMlMh|ryP MWWyN|UzOTB{MB?=
MCF7 Ml;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{iyelczKGh? M1LnemROW09? MU\JR|UxRTJwNUeg{txO MnrFNlM2OjFyMkC=
NCI-H460 MnXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGGzfFQ4OiCq NVzUb2c{TE2VTx?= MkLnTWM2OD16Lkm5JO69VQ>? NYG2enU4OjN3MkGwNlA>
DLD1 NFizR4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn75O|IhcA>? M3rzOGROW09? NGLDSlhKSzVyPUSuOkDPxE1? MknNNlM2Pjd7NkC=
NCI-H661 MnfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPRVnhGPzJiaB?= MoXSSG1UVw>? M1jFT2lEPTB;Nz64JO69VQ>? NGXxSY8zOzV4N{m2NC=>
A549 NGTuVllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PxOlczKGh? NWryUINLTE2VTx?= NGXOO|dKSzVyPUiuNkDPxE1? Ml3TNlM2Pjd7NkC=
U937 M2LYWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV:3NkBp NXTtZYM6TE2VTx?= NX64bm5ZUUN3ME2xNk4zKM7:TR?= MXWyN|U3Pzl4MB?=
HEK293 MVnGeY5kfGmxbjDBd5NigQ>? NXjOOHFmOTEEoN88US=> M{HsZWROW09? NXrU[4QzUW6mdXPld{BjcW6maX7nJIFn\mmwaYT5JJRwKGi3bXHuJIZ2dGxvbHXu[5RpKEircz30ZYdo\WRiTYn0NUBscW6jc3Wg[ZhxemW|c3XkJIlvKEiHS{K5N{Bk\WyuczD3bZRpKEmFNUCgc4YhOC5yNkROwG0> MkPyNlI4PzB4MUC=
HUVEC MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn[3NE4yPcLizszN NHLZeXU4OiCq MV7EUXNQ MYnJcoR2[2W|IHHueIlidmerb3flcolkKGGldHn2bZR6KGmwIFjVWmVEKGOxLXP1cJR2emWmIIfpeIghfmG|Y4XsZZIhe22xb4ToJI12e2OuZTDj[YxteyCjc4Pld5Nm\CCjczDJcohq[mm2aX;uJI9nKGOnbHyg[5Jwf3SqIHH0JFAvOTVidV2= MX[yNlg2Ozl7Mx?=
HUVEC M2PTRmZ2dmO2aX;uJGF{e2G7 NGPm[YMyPcLizszN NGG5Zpg4OiCq MVXEUXNQ MWnJcoR2[2W|IHHueIlidmerb3flcolkKGGldHn2bZR6KGmwIFjVWmVEKGOxLXP1cJR2emWmIIfpeIghfmG|Y4XsZZIhe22xb4ToJI12e2OuZTDj[YxteyCjc4Pld5Nm\CCjczDJcohq[mm2aX;uJI9nKG6ndIfvdosh\m:{bXH0bY9vKGG2IEGuPEB1dyBzNTD1US=> MVKyNlg2Ozl7Mx?=
Plasmodium falciparum M32yW2Z2dmO2aX;uJGF{e2G7 NFHuU|AyOMLizszN MoLGNVUhdWmw NHe1OI9FVVOR NF6ySYFKdmirYnn0d{BRdGG|bX;kbZVuKG[jbHPpdIFzfW1icILvcIln\XKjdHnvckBjgSCrbnjpZol1cW6pIITo[UBHfW6ldHnvckBw\iCSZlPEVGsyKHC{b4TlbY4hf2m2aDDJR|UxKG:oIEGuNVfPxE1? NWjkeFl2OjR3NUCzN|A>
PC3 MXTGeY5kfGmxbjDBd5NigQ>? NELFSYYxNjFizszN NWHkV3JEPSCq NXPXWHFkTE2VTx?= M2HVUGlvcGmkaYTzJIh2dWGwIGDDN{Bk\WyuIHHkbIV{cW:wIHH0JFExOCCwTR?= NV7U[GhMOTl2NkK5O|U>
DU145 M1\EXGZ2dmO2aX;uJGF{e2G7 M1zKb|AvOSEQvF2= NW\5Xm1qPSCq Ml;zSG1UVw>? NFHofGdKdmirYnn0d{BpfW2jbjDEWVE1PSClZXzsJIFlcGW|aX;uJIF1KDFyMDDuUS=> MYqxPVQ3Ojl5NR?=
PC3 NFTKTWNMcW6jc3WgRZN{[Xl? MV6wMlEh|ryP M1;Oe|UhcA>? MXPEUXNQ NWjHd|N1UW6qaXLpeJMh[1O{YzDpckBpfW2jbjDQR|Mh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKFO{YzDZOFE3KGyndnXsJIF1KDFyMDDuUS=> MUmxPVQ3Ojl5NR?=
DU145 MnPzT4lv[XOnIFHzd4F6 NIn6XFAxNjFizszN NFfKc442KGh? NYjM[oJnTE2VTx?= M1i4TmlvcGmkaYTzJINUemNiaX6gbJVu[W5iRGWxOFUh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKFO{YzDZOFE3KGyndnXsJIF1KDFyMDDuUS=> NGO2dJMyQTR4Mkm3OS=>
PC3 M4\RO2tqdmG|ZTDBd5NigQ>? MlzoNE4yKM7:TR?= M2nkSlUhcA>? MmfGSG1UVw>? MYnJcohq[mm2czDjV5JkKGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YheGixc4Doc5J6dGG2ZXSgSmFMKFl3N{[vXVU4PyCuZY\lcEBifCBzMECgcm0> NWX5dGF[OTl2NkK5O|U>
DU145 MXTLbY5ie2ViQYPzZZk> MnniNE4yKM7:TR?= M1XOZlUhcA>? NIfSfmFFVVOR NH\td3RKdmirYnn0d{BkW3KlIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCxZjDwbI9{eGixconsZZRm\CCIQVugXVU4Pi:\NUe3JIxmfmWuIHH0JFExOCCwTR?= MoXKNVk1PjJ7N{W=
Huh7 NHKzNXZCdnSrdnnyZYwhSXO|YYm= MlzzNk42KM7:TR?= MmLsOEBl[Xm| MVnEUXNQ NFqxVZhKdmirYnn0d{B3cXKjbDDzdJJm[WRiaX6gSIVv\3WnII\pdpV{NWmwZnXjeIVlKGi3bXHuJGh2cDdiY3XscJMh[XO|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJI9nKH[rcnHsJIVvfmWub4DlJJBzd3SnaX6ge4l1cGmwIIDldolvfWOuZXHyJJJm\2mxbjDheEAzNjVidV2= NXfRcXRrOTd|NkC2O|Y>
C6/36 MX7BcpRqfmm{YXygRZN{[Xl? MVGyMlUh|ryP M2C1cVQh\GG7cx?= MlPVSG1UVw>? NGH4TpNKdmirYnn0d{B3cXKjbDDzdJJm[WRiaX6gSIVv\3WnII\pdpV{NWmwZnXjeIVlKGG|aXHuJJRq\2W{IH3vd5F2cXSxIFO2M|M3KGOnbHzzJIF{e2W|c3XkJIF{KGGlY4XteYxifGmxbjDv[kB3cXKjbDDlcpZmdG:yZTDwdo91\WmwIIfpeIhqdiCyZYLpcpVkdGWjcjDy[Ydqd25iYYSgNk42KHWP MVqxO|M3ODZ5Nh?=
U937 M1TDb2Z2dmO2aX;uJGF{e2G7 NEnEc4UyKM7:TR?= NVXTeII6OSCq NVyy[lNoTE2VTx?= M1S5UXJm\HWlZYOgZoF{[WxiVF7GZYxxcGFicnXs[YF{\SCrbjDoeY1idiCXOUO3JINmdGy| MnrmNVc3QDRyOUm=
U937 MVnGeY5kfGmxbjDBd5NigQ>? MWOxJO69VQ>? MWGxJIg> Ml;ISG1UVw>? M1;NUnJm\HWlZYOgUHBUNWmwZIXj[YQhXE6IYXzwbIEhemWuZXHz[UBqdiCqdX3hckBWQTN5IHPlcIx{ NYfCTWNDOTd4OESwPVk>
murine mast cell MWTGeY5kfGmxbjDBd5NigQ>? MYWxJO69VQ>? MYqyOEBp MkfsSG1UVw>? MV7Jcohq[mm2czDhcpRq\2WwLXnu[JVk\WRiSVy2JJNm[3KndHnvckBqdiCLZ1WgdJJqdWWmIH3veZNmKG2jc4SgZ4VtdHNiYYSgNUB2VQ>? NVPM[FhJOTd4OESwPVk>
BV-173 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrDTWM2OD1yLkCwNFAxODFyOTFOwG0> MYLTRW5ITVJ?
K-562 NFfobHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLEXXpKSzVyPUCuNFAxODByMk[2JO69VQ>? MkDkV2FPT0WU
BL-70 NX\1OmR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17rVWlEPTB;MD6wNFAxODB6MkKg{txO M{DiNHNCVkeHUh?=
EM-2 NFjUPG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTBwMECwNFAyODhizszN NWKyRlZ5W0GQR1XS
LAMA-84 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWi0elVbUUN3ME2wMlAxODByM{KxJO69VQ>? MX3TRW5ITVJ?
MEG-01 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7BWmJKSzVyPUCuNFAxODB7ODFOwG0> M3XFWHNCVkeHUh?=
EoL-1-cell NWHrVoR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLSTWM2OD1yLkCwNFAyOzFizszN Ml:yV2FPT0WU
CTV-1 NVnMUVY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTBwMECwNFQxPCEQvF2= M1PLXHNCVkeHUh?=
TE-15 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYK0c21kUUN3ME2wMlAxPTh7IN88US=> M1zWeXNCVkeHUh?=
NOS-1 M3rJTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPITWM2OD1yLkCwOlE{KM7:TR?= MknGV2FPT0WU
D-336MG NHX3WGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvhW21KSzVyPUCuNFA3OyEQvF2= NXrPemZIW0GQR1XS
LB1047-RCC M3\nNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTiSnBFUUN3ME2wMlAxQTh7IN88US=> MWnTRW5ITVJ?
LB996-RCC MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;3eFNKSzVyPUCuNFA6QTFizszN NFrvcXNUSU6JRWK=
SW982 NUfGcJZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTBwMEGxNVUh|ryP NH7rZpBUSU6JRWK=
TK10 M{TiW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4O4VWlEPTB;MD6wNVE4PCEQvF2= NVrR[Xp5W0GQR1XS
A704 NYXtcFJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTBwMEG0PVEh|ryP M{C3ZXNCVkeHUh?=
TE-8 MkDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;QXGlEPTB;MD6wNVU4PiEQvF2= MkfMV2FPT0WU
DOHH-2 M1XUcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEKzNIhKSzVyPUCuNFE4OTlizszN NHfDc3VUSU6JRWK=
HOP-62 MkflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXSTWM2OD1yLkCxPFM1KM7:TR?= MmLXV2FPT0WU
TE-12 M37zXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorJTWM2OD1yLkCxPFYyKM7:TR?= MXzTRW5ITVJ?
KGN NYLxTohbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnkNGFKSzVyPUCuNFE6PDJizszN MXfTRW5ITVJ?
NCI-H1648 M3Htfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXId2oxUUN3ME2wMlAzODFzIN88US=> M2n0ZXNCVkeHUh?=
OS-RC-2 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTBwMEKwN{DPxE1? MoL2V2FPT0WU
GB-1 NGHKcFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTBwMEKxOVch|ryP MoPIV2FPT0WU
RXF393 NHvrfW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorsTWM2OD1yLkCyN|U4KM7:TR?= NWDmNHlCW0GQR1XS
LC-2-ad M3TVTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWOwT5dKUUN3ME2wMlAzPTh4IN88US=> M4rqPHNCVkeHUh?=
KS-1 NVHn[WJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTBwMEK3N{DPxE1? MYrTRW5ITVJ?
ETK-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfNTWRbUUN3ME2wMlAzQDN{IN88US=> M1O3[3NCVkeHUh?=
SW954 NWTPbmNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGe4[IhKSzVyPUCuNFI6OjdizszN NEHzNWZUSU6JRWK=
Becker M1H2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{K3ZWlEPTB;MD6wN|AxOyEQvF2= NVHQRYg4W0GQR1XS
MZ1-PC M1fheWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjVd2tKSzVyPUCuNFMyOTlizszN NGPoZm1USU6JRWK=
ES6 MmHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTBwMEOxPVMh|ryP NHvhb3JUSU6JRWK=
KURAMOCHI MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGn4SoxKSzVyPUCuNFM1QDdizszN NETsTJZUSU6JRWK=
CGTH-W-1 MonpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFL0fXBKSzVyPUCuNFM2PDhizszN MVLTRW5ITVJ?
VA-ES-BJ MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnyU3hKSzVyPUCuNFM6ODJizszN Mn\wV2FPT0WU
LXF-289 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\h[WlEPTB;MD6wN|k2PiEQvF2= NUXuXJo4W0GQR1XS
MPP-89 NXHTVph4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTBwMESwOFkh|ryP MV3TRW5ITVJ?
SW872 NHnNNmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoC0TWM2OD1yLkC0NVYyKM7:TR?= NUS1foh6W0GQR1XS
SNB75 M{DS[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfoW2RKSzVyPUCuNFQ1OzVizszN NWrPOnI2W0GQR1XS
PSN1 NIXUXJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHywd|hKSzVyPUCuNFQ1PzRizszN Ml;mV2FPT0WU
LB831-BLC NUHENlA{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zZdmlEPTB;MD6wOFYxQSEQvF2= NWqwSnE4W0GQR1XS
MFH-ino MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTBwMES3NlQh|ryP NITXdFRUSU6JRWK=
TGBC24TKB NXzZeZpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XNVmlEPTB;MD6wOFc3OSEQvF2= M3TGcHNCVkeHUh?=
A388 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWeySJFMUUN3ME2wMlA2ODl3IN88US=> MXXTRW5ITVJ?
BB30-HNC NFy2fFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLCUG1KSzVyPUCuNFU1OzdizszN MWDTRW5ITVJ?
GI-ME-N MlrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHFUFFKSzVyPUCuNFYyOThizszN NFLSPVhUSU6JRWK=
TGBC1TKB NED1[5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\xfZhKSzVyPUCuNFYyPjRizszN NEjpbYZUSU6JRWK=
TE-10 NH3lN2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\hVFU2UUN3ME2wMlA3OzV5IN88US=> M4rVPHNCVkeHUh?=
A498 MnO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXOyWIltUUN3ME2wMlA4Ojh2IN88US=> MkW4V2FPT0WU
TE-11 MlWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HVfGlEPTB;MD6wO|g2QCEQvF2= M33vPHNCVkeHUh?=
BB65-RCC M3vtOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTvUHFsUUN3ME2wMlA5OjJ5IN88US=> MWjTRW5ITVJ?
C2BBe1 NXz3OZd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDMTWM2OD1yLkC4N|A5KM7:TR?= NGPhW|NUSU6JRWK=
NCI-H747 MkHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTBwMEizOlIh|ryP NWDIdVZPW0GQR1XS
IST-MES1 NHv3cWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF[yZWNKSzVyPUCuNFg2PTJizszN Mke5V2FPT0WU
KALS-1 NG\NclBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\XVVZGUUN3ME2wMlA6PDlizszN M1PibHNCVkeHUh?=
GCIY MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTMTGJGUUN3ME2wMlA6PjV4IN88US=> NH3hXlNUSU6JRWK=
RL95-2 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTBwMUCzPEDPxE1? Mm\yV2FPT0WU
TE-1 MlHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHwVpRKSzVyPUCuNVA2PCEQvF2= NGHxOFhUSU6JRWK=
NCI-H1355 NYDsTVhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M321[2lEPTB;MD6xNVAzQCEQvF2= M2HEW3NCVkeHUh?=
SW962 NH7vWlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\DeJhVUUN3ME2wMlEyOjl{IN88US=> NETWT2tUSU6JRWK=
KLE NF7GZ4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HEd2lEPTB;MD6xNVMyPyEQvF2= M2T4NnNCVkeHUh?=
MC116 Mn20S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XkdGlEPTB;MD6xNVQyKM7:TR?= M3HKSHNCVkeHUh?=
NMC-G1 NVzIU5U{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPkUFBKSzVyPUCuNVE3ODZizszN MnLsV2FPT0WU
KU812 M3LZV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHoWI5KSzVyPUCuNVE5QDNizszN MX;TRW5ITVJ?
COLO-829 MmDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7CN|VKSzVyPUCuNVIzOTNizszN NHLNSHNUSU6JRWK=
NTERA-S-cl-D1 NFHxfYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkG4TWM2OD1yLkGyNlg{KM7:TR?= NVq1bFV[W0GQR1XS
IST-MEL1 MnGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fqOWlEPTB;MD6xN|Q2KM7:TR?= M2GwV3NCVkeHUh?=
MLMA M{TGW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTBwMUSwN|Ih|ryP MYHTRW5ITVJ?
LS-123 M{j6RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTBwMUSwOlQh|ryP MXnTRW5ITVJ?
LB2518-MEL Mn3KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTBwMUSxOlIh|ryP MnnYV2FPT0WU
NB69 NFz5ZYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLwNJNKSzVyPUCuNVQ1OzZizszN NWTJ[JVHW0GQR1XS
8-MG-BA MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrkTINbUUN3ME2wMlE2PDV6IN88US=> M3jLcXNCVkeHUh?=
K5 MoW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PIR2lEPTB;MD6xOlQ5QSEQvF2= M4fQWXNCVkeHUh?=
KINGS-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTBwMU[2OlYh|ryP MV3TRW5ITVJ?
SF268 M1TIb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XFfGlEPTB;MD6xO|QxPCEQvF2= MnLnV2FPT0WU
PF-382 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkP3TWM2OD1yLkG3Olc5KM7:TR?= NIWwOlVUSU6JRWK=
SH-4 NFq4dHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrmTWM2OD1yLkG4OFE{KM7:TR?= NEX0W4hUSU6JRWK=
NALM-6 MlH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jMbWlEPTB;MD6xPVI6PSEQvF2= NVf4b2VmW0GQR1XS
CP66-MEL NELlS4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NID0SHNKSzVyPUCuNVk2OzFizszN NF34eXdUSU6JRWK=
697 MmnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVe5fWJVUUN3ME2wMlE6QTh5IN88US=> NVPNUZJMW0GQR1XS
CP67-MEL MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTBwMkC0PFgh|ryP MX\TRW5ITVJ?
DSH1 M1LHdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULIRpBjUUN3ME2wMlI1ODBzIN88US=> NEL0c|VUSU6JRWK=
HCE-4 Ml20S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\NV3pKSzVyPUCuNlY1OzlizszN MXrTRW5ITVJ?
MZ2-MEL NEnUOnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWS5NHJQUUN3ME2wMlI5PTN5IN88US=> NV35b2NGW0GQR1XS
BL-41 NYDrdpR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTBwMkmxNlMh|ryP MVzTRW5ITVJ?
HUTU-80 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmL0TWM2OD1yLkOxOFIh|ryP NIfnVGVUSU6JRWK=
LOXIMVI MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nRbWlEPTB;MD6zNVUxOyEQvF2= NG\H[XlUSU6JRWK=
no-10 M3vTXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPUTWM2OD1yLkOxPVMyKM7:TR?= MUfTRW5ITVJ?
KARPAS-422 M{XpNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUW1b5RqUUN3ME2wMlM{QTl5IN88US=> M2nGZnNCVkeHUh?=
SW684 NXu5eVRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TFU2lEPTB;MD6zOFk5KM7:TR?= NIG0RmVUSU6JRWK=
SF126 MmL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfPeVlKSzVyPUCuN|U1OSEQvF2= NVKwb25YW0GQR1XS
D-263MG NFHoVpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPWeJU3UUN3ME2wMlM3OjJ2IN88US=> M2\uXXNCVkeHUh?=
OVCAR-4 Ml;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonQTWM2OD1yLkO3OFM{KM7:TR?= NF\sZopUSU6JRWK=
BB49-HNC NHnuZnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjNN|dGUUN3ME2wMlM5PTl7IN88US=> MlLDV2FPT0WU
ONS-76 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFn3OXRKSzVyPUCuOFI6PTFizszN NH7GNW9USU6JRWK=
MZ7-mel M3q2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrURmJuUUN3ME2wMlQ4QTFzIN88US=> NXjWfWlvW0GQR1XS
RCC10RGB M1\Lfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvCbYNJUUN3ME2wMlQ6OTFizszN MWPTRW5ITVJ?
BOKU NUX4TY54T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;aOHZlUUN3ME2wMlQ6OTN|IN88US=> NGqzUHFUSU6JRWK=
no-11 Mnr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPjTWM2OD1yLkWwNlI5KM7:TR?= NVrWb4tDW0GQR1XS
IST-SL2 M1zqdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HJO2lEPTB;MD61NFMxOiEQvF2= Mn63V2FPT0WU
RKO MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTBwNUK5OlYh|ryP MWjTRW5ITVJ?
HT-144 M1PDZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTBwNUO2NFkh|ryP MXHTRW5ITVJ?
NCI-H446 MlnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnzTWM2OD1yLk[yO|Yh|ryP MnXsV2FPT0WU
QIMR-WIL M3zoVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHsZoJKSzVyPUCuO|A3OjlizszN Ml3KV2FPT0WU
MHH-PREB-1 NHzCTIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTBwN{S0Olkh|ryP MVjTRW5ITVJ?
EW-16 MkXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7tWZRKSzVyPUCuO|YyPzhizszN MlzlV2FPT0WU
EW-24 NGK4clhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoP2TWM2OD1yLke4NVY2KM7:TR?= MUXTRW5ITVJ?
LB373-MEL-D MmPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\qUo9UUUN3ME2wMlgzPTB6IN88US=> M{Htd3NCVkeHUh?=
TE-9 NHzWd25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTBwOEe1N|Ih|ryP NVOxNnU5W0GQR1XS
A3-KAW M2\NeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13TdmlEPTB;MD65PFQ2OiEQvF2= MYPTRW5ITVJ?
A101D Mkn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mln1TWM2OD1zLkCzNFQ{KM7:TR?= MW\TRW5ITVJ?
OCUB-M M4jB[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTFwMES0NVIh|ryP M2XmenNCVkeHUh?=
ES4 MmPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33yR2lEPTB;MT6wOVE1PSEQvF2= NV;rUopWW0GQR1XS
TE-6 NGPidllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3oXVY5UUN3ME2xMlIyOjJ4IN88US=> MVfTRW5ITVJ?
D-502MG M{mzZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LsSmlEPTB;MT6yN|M4PiEQvF2= M1y5RXNCVkeHUh?=
KNS-42 M1fmdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nhOWlEPTB;MT6yOFQyOiEQvF2= NIjZdHFUSU6JRWK=
SNU-C2B NHi0dG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjLVJpKSzVyPUGuN|A2QDlizszN Mm\wV2FPT0WU
NCI-H1838 NILtbZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jGc2lEPTB;MT6zNFc{OyEQvF2= MXHTRW5ITVJ?
NKM-1 MnLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TEN2lEPTB;MT6zNFg2QSEQvF2= M4TjcHNCVkeHUh?=
GI-1 MkPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;NfHRKSzVyPUGuN|YzOiEQvF2= M3jYWHNCVkeHUh?=
NB5 M37Ecmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTFwM{m4Nlch|ryP M3fkW3NCVkeHUh?=
CAS-1 NID1ZWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHj0d3hKSzVyPUGuOFA6QTJizszN NGrp[WRUSU6JRWK=
HCE-T NUHiXFRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTFwNU[3NVQh|ryP M{XWbnNCVkeHUh?=
SBC-1 M4XUcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XxS2lEPTB;MT61O|k5PCEQvF2= NHfWXphUSU6JRWK=
JiyoyeP-2003 MmfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTFwN{O0OlYh|ryP MUPTRW5ITVJ?
TE-5 M1LkcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTFwN{mxN|kh|ryP MoO5V2FPT0WU
CAN NGLQSWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rpdmlEPTB;MT64NlI2OiEQvF2= NIW2VWxUSU6JRWK=
SK-UT-1 NHP6SWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfINo5{UUN3ME2yMlE3Pjl|IN88US=> MlrUV2FPT0WU
JVM-2 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7RO2tKSzVyPUKuN|YzQDRizszN MULTRW5ITVJ?
LB771-HNC NFz6bm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEX5Z3pKSzVyPUKuOVc2PTFizszN NV3BT|MxW0GQR1XS
NCCIT NULmXZV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDLTWM2OD1{Lki2OlE3KM7:TR?= MXHTRW5ITVJ?
NCI-H2126 M1\Lemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTJwOEe1OVIh|ryP NGf3V49USU6JRWK=
Calu-6 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHTcWdWUUN3ME2zMlA2PzRzIN88US=> MWrTRW5ITVJ?
SK-LMS-1 M3jvXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDETWM2OD1|LkGxPFg3KM7:TR?= Mn;3V2FPT0WU
ARH-77 NFe5NFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTvNnE1UUN3ME2zMlQ3QTF3IN88US=> MofzV2FPT0WU
NB17 Mo\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nleGlEPTB;Mz62N|g1PyEQvF2= NHrB[2VUSU6JRWK=
A253 M{W2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfjUoVKSzVyPUOuO|MzPDZizszN MYjTRW5ITVJ?
OPM-2 NV7oRZo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYezbVZpUUN3ME20MlI4Pjh3IN88US=> MV7TRW5ITVJ?
MV-4-11 NVvuRllmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7XdYVKSzVyPUSuN|Y1PTRizszN NYnpVWM6W0GQR1XS
SR NGXLVWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDOe3RsUUN3ME20MlQ6QTV2IN88US=> NF;rRXVUSU6JRWK=
KG-1 MkDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTRwNkC4OFUh|ryP MUPTRW5ITVJ?
OCI-AML2 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHp[417UUN3ME21Mlg3OTV2IN88US=> NV\uVJh4W0GQR1XS
D-247MG NHPaR5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTZwMUK1NVkh|ryP NWPhfod2W0GQR1XS
DJM-1 NXPIcnJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFH1cJNKSzVyPU[uOFg2PThizszN MYfTRW5ITVJ?
RPMI-6666 NXHHOoRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkGzTWM2OD15LkK3NFY4KM7:TR?= NFzJfXFUSU6JRWK=
KARPAS-45 NWCwb4R7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTdwNUG2O|Eh|ryP M1fsN3NCVkeHUh?=
LP-1 M4Du[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1e3RWlEPTB;Nz61OFc5OiEQvF2= NGTySppUSU6JRWK=
RS4-11 NUXFdINVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrjfo5tUUN3ME23MlY2Pzh5IN88US=> MXrTRW5ITVJ?
DU-4475 MkS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRThwMkG2OVIh|ryP M3TYTHNCVkeHUh?=
MONO-MAC-6 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRThwMkewOlYh|ryP NHHsb4JUSU6JRWK=
NCI-SNU-16 MorXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\PbGlEPTB;OD61OlEzQCEQvF2= NE\0UIZUSU6JRWK=
SJSA-1 NInEOlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\FVWlEPTB;OD63NlgxPSEQvF2= M4PlXXNCVkeHUh?=
MMAC-SF M3O2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWD3b3BiUUN3ME24Mlc6OzB5IN88US=> MV7TRW5ITVJ?
SK-NEP-1 MoS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LhSmlEPTB;OD64PVE2PSEQvF2= MmfHV2FPT0WU
J-RT3-T3-5 NXLKUI45T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{W5OWlEPTB;OD65OlUzQSEQvF2= NUXGWopzW0GQR1XS
SKM-1 NV3MR|ZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTlwMEG3N|Qh|ryP NYLEZos1W0GQR1XS
LB2241-RCC M1LNSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjmO2tIUUN3ME25MlAzODF{IN88US=> MluyV2FPT0WU
SIG-M5 M3TpRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HYNWlEPTB;OT6wNlQ6OyEQvF2= NFvPfWRUSU6JRWK=
EVSA-T NYH6OlcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{WySGlEPTB;OT6yO|c6OyEQvF2= MWjTRW5ITVJ?
GT3TKB NEX0ZWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;Lc4Z{UUN3ME25MlM2PTR4IN88US=> NF;FbItUSU6JRWK=
NB6 MlmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\0NG1KUUN3ME25MlkzOjV7IN88US=> NV\h[JhyW0GQR1XS
EHEB M2TCSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETTR2JKSzVyPUGwMlA3PTZizszN MoPsV2FPT0WU
HEL NX\qUItnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTGTWM2OD1zMD60O|c3KM7:TR?= M2nVTXNCVkeHUh?=
ALL-PO M3TOT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTFyLke5N|gh|ryP NVTWXHBNW0GQR1XS
TGW MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTFzLkK4Nlgh|ryP M1TyWXNCVkeHUh?=
BC-3 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTF{LkGxN|gh|ryP NX7wWlhHW0GQR1XS
IA-LM NFLISW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXNTWM2OD1zMj60OFQ2KM7:TR?= NVLxTGdnW0GQR1XS
UACC-257 NGXKfoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTF{LkmxPVgh|ryP Mny5V2FPT0WU
KP-N-YS MkL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXaTWM2OD1zMj65Nlg{KM7:TR?= NYn0NmJmW0GQR1XS
Raji Mli0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\xRYJKSzVyPUGzMlc1QTdizszN NXrJOoQ2W0GQR1XS
SF539 NGLBRYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTF|Lki1OVch|ryP M364RnNCVkeHUh?=
DMS-153 NHn2OpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUewb21DUUN3ME2xOE4xODJ6IN88US=> MXfTRW5ITVJ?
L-540 NEC5V4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTF3LkC2O|Ih|ryP MUnTRW5ITVJ?
MN-60 NELGV|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXriNHM6UUN3ME2xOU4yQTd7IN88US=> MV\TRW5ITVJ?
RPMI-8866 M1nQdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTGdoJEUUN3ME2xO{41PDV2IN88US=> NELaU21USU6JRWK=
NCI-H510A NHrCb|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLY[I5[UUN3ME2xPU4{QTd|IN88US=> M2fpXHNCVkeHUh?=
NB13 MkKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjYZlZ[UUN3ME2xPU41QDd5IN88US=> NHz4[2hUSU6JRWK=
HAL-01 Mk[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVy4Sm12UUN3ME2xPU44PTR|IN88US=> M4LvdXNCVkeHUh?=
NCI-H720 M{LrWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHS5SnhKSzVyPUKwMlI4OzNizszN NGnMS5pUSU6JRWK=
REH MoS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTJyLk[zOVch|ryP NIK3V3ZUSU6JRWK=
KNS-81-FD NGHEV5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTJ|LkG0OkDPxE1? MUfTRW5ITVJ?
HC-1 NVrRfZl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnyTWM2OD1{ND61OVUyKM7:TR?= M1zkfHNCVkeHUh?=
NCI-H2141 Mlj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTVTWM2OD1{ND63O|U1KM7:TR?= M2DUeHNCVkeHUh?=
MOLT-4 NELN[FBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LEcGlEPTB;Mk[uOlc2OyEQvF2= M2XYeHNCVkeHUh?=
OMC-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\xTWM2OD1{Nz6xOFIzKM7:TR?= MXXTRW5ITVJ?
LC-1F M3fUdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTJ5LkOyOFUh|ryP MmrhV2FPT0WU
NCI-H1304 Ml3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHtOmp2UUN3ME2yPE4yPjJ6IN88US=> M1npcXNCVkeHUh?=
BC-1 M1PTZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLVS2dKSzVyPUK4MlY2OSEQvF2= M1HBVHNCVkeHUh?=
NCI-H64 NUnXXoRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7VT4NQUUN3ME2yPU43OjV|IN88US=> NX;Q[WFoW0GQR1XS
MOLT-16 MnTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEj1UWFKSzVyPUK5MlYzQTJizszN NUHCXY1GW0GQR1XS
U-87-MG MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvXcpU6UUN3ME2zNE44PjZizszN MXfTRW5ITVJ?
GAK NF72S3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{f4WmlEPTB;M{GuNlY5PiEQvF2= M1\INXNCVkeHUh?=
ES8 M{[1U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTN{LkGyOVIh|ryP M4P0WXNCVkeHUh?=
HCC1599 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHFTWM2OD1|Mj6zN|I2KM7:TR?= Mn7rV2FPT0WU
EB-3 M2PRW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4qyTmlEPTB;M{SuN|EyPyEQvF2= MmPjV2FPT0WU
HCC1187 NGLsWWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnr[nFJUUN3ME2zOU45ODV{IN88US=> MmXPV2FPT0WU
SK-PN-DW M4r2SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTN4LkG5OFMh|ryP MXPTRW5ITVJ?
JVM-3 MoLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTN5LkKzN|gh|ryP MonFV2FPT0WU
HCC2157 NXTqcXRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\LNGlEPTB;M{euPVk1PiEQvF2= NF70OWxUSU6JRWK=
A4-Fuk NFPPPFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3Y[ZJKSzVyPUO4MlExODlizszN M3PkT3NCVkeHUh?=
COR-L279 M{L2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\FTWM2OD12MD6yPFUyKM7:TR?= NXnrcFBXW0GQR1XS
DEL MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDafI53UUN3ME20NU46ODh4IN88US=> MmLIV2FPT0WU
NCI-H1395 NF3yOlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvsPIhKSzVyPUSyMlAyPjNizszN NVLSZ5pqW0GQR1XS
MHH-NB-11 NX\XVm1CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;TWFRKUUN3ME20N{4xQDF6IN88US=> MXzTRW5ITVJ?
NCI-H2107 MlvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljkTWM2OD12Mz60PFQ3KM7:TR?= NFjaWG9USU6JRWK=
NEC8 Mln1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLvU|FKSzVyPUS0MlM{PiEQvF2= NW\hcXlOW0GQR1XS
COLO-684 MmPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPVdZFvUUN3ME20Ok4zOjV6IN88US=> M1TYfHNCVkeHUh?=
LS-411N NWfsZWw1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoezTWM2OD12OD60O|Q5KM7:TR?= NHjkN2pUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo試験 Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. [3]
臨床試験 Dasatinib has entered in a phase II clinical trial in the treatment of hemangiopericytoma and gastrointestinal stromal tumor.
特集

プロトコル (参考用のみ)

キナーゼアッセイ:

[1]

Kinase autophosphorylation assays Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.

細胞アッセイ:

[1]

細胞株 Ba/F3 cell lines
濃度 ~32 nM
反応時間 72 hours
実験の流れ

Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I.

動物実験:

[3]

動物モデル EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC)
製剤 DMSO
投薬量 30 mg/kg
投与方法 Administered via i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Dasatinib SDF
分子量 488.01
化学式

C22H26ClN7O2S

CAS No. 302962-49-8
保管 2年-20℃
6月-80℃in solvent
別名 BMS-354825
溶解度 (25°C) * In vitro DMSO 98 mg/mL (200.81 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo 4% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide

文献中の引用 (62)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related Src 阻害剤

  • Dasatinib Monohydrate

    Dasatinib Monohydrate is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.

  • SU6656

    SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.

  • PX-478 2HCl

    PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. Phase 1.

  • Defactinib (VS-6063, PF-04554878)

    Defactinib (VS-6063, PF-04554878) is a selective, and orally active FAK inhibitor. Phase 2.

  • Saracatinib (AZD0530)

    Saracatinib(AZD0530)は、c-SrcのためのSrc阻害剤で、IC50 が2.7 nMです。

    Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.

  • Bosutinib (SKI-606)

    Bosutinib(SKI-606)はそれぞれ1.2nMと1nMのIC50値による新しい二重Sarcoma/アベルソン(Src/Abl)チロシン・キナーゼ阻害剤です。

  • KX2-391

    KX2-391は、Srcのサブストレート結合部位を目標とする非常に選択的な非ATP Srcキナーゼ阻害剤で、Srcの高水準を表すガン細胞線で、非常に強い反増殖的な活性を示します。

  • PP1

    PP1は、Lck/Fynのための強力で選択的なSrc阻害剤で、IC50 が 5 nM/ 6 nMです。

  • PP2

    PP2は、Src キナーゼ阻害剤で、GST-Src活動を強力に禁止します。

最近チェックしたアイテム

Tags: Dasatinibを買う | Dasatinib供給者 | Dasatinibを購入する | Dasatinib費用 | Dasatinib生産者 | オーダーDasatinib | Dasatinib代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ